News Pharma urges NHS to put medicines at heart of 10-year plan The UK pharma industry has warned that declining access to new medicines in England will undermine the government's efforts to rebuild the NHS.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
Patients 3 Ways to improve the patient experience in clinical trials The patient experience in healthcare is often the focal point of interaction between patients and their clinicians.
News Bayer reveals phase 3 data for improved MRI contrast agent Bayer is close to filing a new MRI contrast agent that can reduce levels of gadolinium, which can have health and environmental consequences.
News Data cues up AZ oral SERD filing in first-line breast cancer AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
News Evidence builds behind Regeneron's deafness gene therapy Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.